Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
4.840
-0.120 (-2.42%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Bolt Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Cash & Equivalents | 11.7 | 7.21 | 10.81 | 9.24 | 27.38 | Upgrade
|
| Short-Term Investments | 15.8 | 40.12 | 91.38 | 159.64 | 158.84 | Upgrade
|
| Cash & Short-Term Investments | 27.51 | 47.32 | 102.19 | 168.89 | 186.22 | Upgrade
|
| Cash Growth | -41.88% | -53.69% | -39.49% | -9.31% | 715.39% | Upgrade
|
| Other Receivables | 0.97 | 1.17 | 0.6 | - | - | Upgrade
|
| Receivables | 0.97 | 1.17 | 0.6 | - | - | Upgrade
|
| Prepaid Expenses | 1.41 | 1.49 | 2.74 | 3.86 | 2.94 | Upgrade
|
| Restricted Cash | 0.2 | 0.78 | - | - | - | Upgrade
|
| Other Current Assets | 0.18 | 0.06 | 0.18 | - | - | Upgrade
|
| Total Current Assets | 30.26 | 50.81 | 105.71 | 172.75 | 189.16 | Upgrade
|
| Property, Plant & Equipment | 20.48 | 24.9 | 24.08 | 28.53 | 30.6 | Upgrade
|
| Long-Term Investments | 4.34 | 22.88 | 26.41 | 23.94 | 85.35 | Upgrade
|
| Long-Term Deferred Charges | 0.14 | 0.05 | 0.37 | - | - | Upgrade
|
| Other Long-Term Assets | 1.54 | 0.99 | 3.22 | 2.59 | 2.61 | Upgrade
|
| Total Assets | 56.75 | 99.63 | 159.78 | 227.81 | 307.72 | Upgrade
|
| Accounts Payable | 1.44 | 1.51 | 2.99 | 3.59 | 3.57 | Upgrade
|
| Accrued Expenses | 2.97 | 8.34 | 12.49 | 15.14 | 12.38 | Upgrade
|
| Current Portion of Leases | 2.83 | 2.25 | 2.78 | 2.39 | 2.5 | Upgrade
|
| Current Unearned Revenue | 0.45 | 3.02 | 2.2 | 1.99 | 2.87 | Upgrade
|
| Other Current Liabilities | 0.74 | 0.74 | - | - | - | Upgrade
|
| Total Current Liabilities | 8.44 | 15.86 | 20.46 | 23.12 | 21.33 | Upgrade
|
| Long-Term Leases | 20.13 | 22.96 | 17.44 | 20.22 | 21.85 | Upgrade
|
| Long-Term Unearned Revenue | 1.54 | 3.62 | 9.11 | 12.92 | 14.21 | Upgrade
|
| Other Long-Term Liabilities | 0.13 | - | 0.04 | 0.04 | 0.21 | Upgrade
|
| Total Liabilities | 30.24 | 42.43 | 47.04 | 56.3 | 57.6 | Upgrade
|
| Additional Paid-In Capital | 487.31 | 484.5 | 476.99 | 467.51 | 457.43 | Upgrade
|
| Retained Earnings | -460.78 | -427.4 | -364.29 | -295.09 | -206.99 | Upgrade
|
| Comprehensive Income & Other | -0.02 | 0.1 | 0.04 | -0.92 | -0.32 | Upgrade
|
| Total Common Equity | 26.51 | 57.2 | 112.74 | 171.51 | 250.12 | Upgrade
|
| Shareholders' Equity | 26.51 | 57.2 | 112.74 | 171.51 | 250.12 | Upgrade
|
| Total Liabilities & Equity | 56.75 | 99.63 | 159.78 | 227.81 | 307.72 | Upgrade
|
| Total Debt | 22.96 | 25.21 | 20.22 | 22.61 | 24.36 | Upgrade
|
| Net Cash (Debt) | 4.55 | 22.11 | 81.97 | 146.28 | 161.86 | Upgrade
|
| Net Cash Growth | -79.44% | -73.02% | -43.96% | -9.63% | 1253.27% | Upgrade
|
| Net Cash Per Share | 2.43 | 11.58 | 43.36 | 78.31 | 97.52 | Upgrade
|
| Filing Date Shares Outstanding | 1.92 | 1.92 | 1.91 | 1.89 | 1.87 | Upgrade
|
| Total Common Shares Outstanding | 1.92 | 1.92 | 1.91 | 1.89 | 1.87 | Upgrade
|
| Working Capital | 21.83 | 34.96 | 85.25 | 149.63 | 167.83 | Upgrade
|
| Book Value Per Share | 13.80 | 29.84 | 59.16 | 90.75 | 133.75 | Upgrade
|
| Tangible Book Value | 26.51 | 57.2 | 112.74 | 171.51 | 250.12 | Upgrade
|
| Tangible Book Value Per Share | 13.80 | 29.84 | 59.16 | 90.75 | 133.75 | Upgrade
|
| Machinery | 8.27 | 10.13 | 10.42 | 10.1 | 8.26 | Upgrade
|
| Leasehold Improvements | 0.36 | 0.29 | 0.29 | 0.27 | 0.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.